Truist Financial’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Truist Financial’s Portfolio NRXPW Stock Details NRXPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,965	Closed	-$3.32K	–	2770
2025 Q2	$3.32K	Hold	38,965	–	–	﹤0.01%	2589
2025 Q1	$3.65K	Hold	38,965	–	–	﹤0.01%	2541
2024 Q4	$4.99K	Hold	38,965	–	–	﹤0.01%	2508
2024 Q3	$1.75K	Hold	38,965	–	–	﹤0.01%	2493
2024 Q2	$2.34K	Buy	+38,965	New	+$4.89K	﹤0.01%	2638

Other funds holding NRXPW

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Truist Financial's NRXPW Position: Q3 2025 in Review

Truist Financial sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q3 2025, closing a stake of 38,965 shares — an estimated $3.32K sold.

Truist Financial first reported a position in NRXPW in Q2 2024 and held it in 5 quarters. The position peaked at $4.99K in Q4 2024. 4 funds tracked by Wall St. Rank hold NRXPW as of Q3 2025.

Truist Financial reported no remaining NRX Pharmaceuticals Warrant position as of Q3 2025 after selling out during the quarter.
Truist Financial sold 38,965 NRX Pharmaceuticals Warrant shares in Q3 2025, an estimated $3.32K.
Truist Financial first reported a position in NRX Pharmaceuticals Warrant in Q2 2024 and held it in 5 quarters.
Truist Financial's NRX Pharmaceuticals Warrant position peaked at $4.99K in Q4 2024.
4 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q3 2025.

Based on Truist Financial's 13F filing for Q3 2025, filed 3 Nov 2025.